Sigrid Therapeutics announced today that recruitment to the SHINE clinical trial, which is evaluating the company's breakthrough product SiPore21® for long-term diabetes control, has been completed.
Sigrid Therapeutics announced today that the company has recruited over 50% of patients in SHINE, a clinical trial evaluating SiPore21® for the treatment of elevated glucose levels.
Sigrid Therapeutics is pleased to announce the start of the SHINE clinical trial for SiPore21® – an innovative medical device designed for long-term maintenance of blood sugar and weight control.
Sigrid Therapeutics, an innovative, consumer-focused health company that has developed a new technology, SiPore ® against prediabetes and obesity, announces today that the company, after 10 years of research, is in the starting blocks to launch its new, clinically proven product SiPore21 ® .
Sigrid Therapeutics, a technology company specializing in the prevention of type 2 diabetes and obesity, announced today that the company has been granted a patent by the United States Patent and Trademark Office (USPTO).
Sigrid Therapeutics announced today that the Company has been named by FierceMedTech as one of the 2019 “Fierce 15” companies, one of the most promising private medtech companies in the industry. This is the first time in its eight-year history that a Swedish company has been included on the list.
Sigrid Therapeutics AB, a biotechnology company developing a new class of therapies in metabolic diseases, today announces that all patients have completed treatment with SiPore15 in the STAR clinical trial.
The leading American life science magazine BioSpace has named Sana Alajmovic one of 10 young life science innovators under the age of 40 to watch in the future.
The leading international life science journal Genetic Engineering News (GEN) has selected Sana Alajmovic, CEO of Sigrid Therapeutics, to this year's highly prestigious Top 10 Under 40 list 2019.
Sigrid Therapeutics today announced the publication of a large study in mice in the peer-reviewed journal Nanomedicine. The study demonstrates enzyme-blocking effects of mesoporous silica particles (MSPs) administered into the intestine with effects on food efficiency and metabolic risk factors as a result.